Dr. Benjamin Tan, MD
Claim this profileWashington University School of Medicine
Studies Colorectal Cancer
Studies Adenocarcinoma
19 reported clinical trials
58 drugs studied
Area of expertise
1Colorectal Cancer
Stage III
Stage IV
BRAF negative
2Adenocarcinoma
Stage III
Stage IV
Stage I
Affiliated Hospitals
Clinical Trials Benjamin Tan, MD is currently running
Cabozantinib
for Neuroendocrine Cancer
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is no extensive literature or consensus on second- or third-line options (which include FOLFOX, FOLFIRI, capecitabine and temozolomide, taxanes or immunotherapy) and there is urgent need for better regimens.
Recruiting1 award Phase 2
Defactinib + Radiotherapy
for Pancreatic Cancer
Patients with advanced pancreas adenocarcinoma will be randomized on a 6:1 basis to receive standard of care chemotherapy followed by adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant FAK inhibitor defactinib (experimental arm) or standard of care chemotherapy followed by SBRT (control arm). Patients enrolled to the experimental arm will be assessed for clinical outcomes such as progression free survival (PFS), local control, distant control, and toxicity. The first 6 patients randomized to the experimental arm will be considered the safety lead-in and will be assessed for dose-limiting toxicities (DLTs). The 6 patients randomized to the control arm will be evaluated for correlatives but will not be included in the analysis for primary and secondary endpoints.
Recruiting1 award Phase 219 criteria
More about Benjamin Tan, MD
Clinical Trial Related6 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Benjamin Tan, MD has experience with
- Nivolumab
- Defactinib
- Leucovorin
- Trastuzumab
- FDG PET/MRI
- Cabozantinib
Breakdown of trials Benjamin Tan, MD has run
Colorectal Cancer
Adenocarcinoma
Rectal Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Benjamin Tan, MD specialize in?
Benjamin Tan, MD focuses on Colorectal Cancer and Adenocarcinoma. In particular, much of their work with Colorectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Benjamin Tan, MD currently recruiting for clinical trials?
Yes, Benjamin Tan, MD is currently recruiting for 5 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Benjamin Tan, MD has studied deeply?
Yes, Benjamin Tan, MD has studied treatments such as Nivolumab, Defactinib, Leucovorin.
What is the best way to schedule an appointment with Benjamin Tan, MD?
Apply for one of the trials that Benjamin Tan, MD is conducting.
What is the office address of Benjamin Tan, MD?
The office of Benjamin Tan, MD is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.